Abstract
BackgroundACE2 is a novel homologue of angiotensin converting enzyme (ACE). ACE2 is highly expressed in human heart and animal data suggest that ACE2 is an essential regulator of cardiac function in vivo. Since overactivity of the renin-angiotensin system contributes to the progression of heart failure, this investigation assessed changes in gene expression of ACE2, ACE, AT1 receptor and renin in the human failing heart.MethodsThe sensitive technique of quantitative reverse transcriptase polymerase chain reaction was used to determine the level of mRNA expression of ACE and ACE2 in human ventricular myocardium from donors with non-diseased hearts (n = 9), idiopathic dilated cardiomyopathy (IDC, n = 11) and ischemic cardiomyopathy (ICM, n = 12). Following logarithmic transformation of the data, a one-way analysis of variance was performed for each target gene followed by a Dunnett's test to compare the two disease groups IDC and ICM versus control.ResultsAs anticipated, ACE mRNA was found to be significantly increased in the failing heart with a 3.1 and 2.4-fold up-regulation found in IDC and ICM relative to non-diseased myocardium. Expression of ACE2 mRNA was also significantly up-regulated in IDC (2.4-fold increase) and ICM (1.8-fold increase) versus non-diseased myocardium. No change in angiotensin AT1 receptor mRNA expression was found in failing myocardium and renin mRNA was not detected.ConclusionsThese data suggest that ACE2 is up-regulated in human IDC and ICM and are consistent with the hypothesis that differential regulation of this enzyme may have important functional consequences in heart failure. This strengthens the hypothesis that ACE2 may be a relevant target for the treatment of heart failure and will hopefully spur further studies to clarify the functional effects in human myocardium of ACE2 derived peptides.
Highlights
ACE2 is a novel homologue of angiotensin converting enzyme (ACE)
Atrial natriuretic factor (ANF) mRNA was evaluated as a positive control and was confirmed to be up-regulated by approximately 13 and 8-fold in idiopathic dilated cardiomyopathy (IDC) and ischemic cardiomyopathy (ICM), respectively, versus the control group
ACE2 mRNA was expressed in non-diseased ventricle and expression was further enhanced in IDC (~2 fold increase) and ICM (~2-fold increase)
Summary
ACE2 is a novel homologue of angiotensin converting enzyme (ACE). ACE2 is highly expressed in human heart and animal data suggest that ACE2 is an essential regulator of cardiac function in vivo. The key product resulting from ACE2-induced hydrolysis of Ang II is Ang 1-7 [2,4], whose functional effects (vasodilator, anti-proliferative) oppose those of Ang II [5,6]. Taken together, these data are shaping the hypothesis that ACE2 may act to balance the activity of the renin-angiotensin system [7]. These data are shaping the hypothesis that ACE2 may act to balance the activity of the renin-angiotensin system [7] This is complemented by an important recent functional study [8], which demonstrated that ACE2 mRNA levels are reduced in several strains of hypertensive rats. Crackower et al demonstrated that targeted disruption of ACE2 in mice results in a cardiac contractility defect, increased cardiac levels of Ang II and upregulation of hypoxia-inducible genes in the heart [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
